| Property |
Value |
| Category |
Inflammatory/Damage Biomarker |
| Target |
HMGB1 protein |
| Sample Type |
CSF, Blood (serum/plasma) |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, Stroke, TBI, ALS, MS, Sepsis-Associated Encephalopathy |
| Sensitivity |
High |
| Specificity |
Moderate (involved in multiple pathways) |
High Mobility Group Box 1 (HMGB1) is a highly conserved nuclear protein that functions as an alarmin when released extracellularly. Initially discovered as a DNA-binding protein involved in transcription regulation, HMGB1 has been recognized as a critical damage-associated molecular pattern (DAMP) molecule that mediates sterile inflammation following tissue injury. In the central nervous system, HMGB1 plays complex roles in neuroinflammation, neurodegeneration, and neural repair.
| Property |
Value |
| Gene |
HMGB1 (formerly HMG1) |
| Protein |
High Mobility Group Box 1 |
| UniProt |
P09429 |
| Molecular Weight |
~25 kDa (215 amino acids) |
| Chromosome |
13q12 |
| Structure |
Two HMG boxes (A and B), acidic C-terminal tail |
HMGB1 contains:
- N-terminal region: Two HMG boxes (A and B) that bind DNA
- C-terminal acidic tail: Consists of 30 aspartic and glutamic acid residues
- Nuclear localization signal: Located in the B-box
- Post-translational modifications: Acetylation, phosphorylation, methylation, oxidation
¶ Cellular Localization and Release
- Nuclear (baseline): Binds to chromatin, regulates gene expression
- Cytoplasmic: Involved in autophagy and cell survival
- Extracellular: Released passively (necrosis) or actively (secretion)
- DNA bending and flexibility
- Transcription regulation (facilitates binding of transcription factors)
- DNA repair
- V(D)J recombination
- Chromatin remodeling
- Pro-inflammatory cytokine when released
- Chemoattractant for immune cells
- Endothelial cell activation
- Neuronal excitotoxicity (in CNS)
- Promotes autophagy in some contexts
- Tissue repair and regeneration
- CSF elevations: Elevated in AD patients vs. controls (Pellicanò et al., 2013)
- Disease correlation: Correlates with disease severity and progression
- Pathogenesis: Involved in amyloid-beta toxicity and neuroinflammation
- Therapeutic target: Anti-HMGB1 strategies being explored
- Combination markers: Often measured with tau and Aβ42
- Elevated levels: Increased in PD CSF and serum (Kong et al., 2019)
- Neuroinflammation: Reflects microglial activation and neuroinflammation
- Disease severity: Correlates with motor scores (UPDRS)
- Progression: May predict disease progression
- α-Synuclein interaction: May be involved in α-synuclein aggregation
¶ Stroke and Ischemic Injury
- Acute release: Released rapidly following cerebral ischemia
- Kinetics: Elevated within hours, peaks at 24-72 hours
- Prognosis: Higher levels predict worse functional outcome
- Hemorrhagic stroke: Also elevated in intracerebral hemorrhage
- Treatment target: Anti-HMGB1 therapies being investigated
- Early marker: Elevated in CSF and blood within hours post-injury
- Severity correlation: Levels correlate with injury severity (GCS)
- Prognosis: Predicts outcome and mortality
- Chronic phase: Remains elevated in chronic TBI
- Second hit: May contribute to secondary injury mechanisms
- Systemic inflammation: Elevated in serum and CSF of ALS patients
- Disease progression: Correlates with progression rate
- Pathogenesis: Contributes to neuroinflammation in ALS
- Microglial activation: Reflects activated glial response
- Active disease: Elevated during MS relapses
- Lesion activity: Associated with gadolinium-enhancing lesions
- Progressive MS: Higher levels in primary progressive MS
- Therapeutic monitoring: May respond to immunomodulatory therapy
- Systemic release: Elevated in sepsis due to systemic inflammation
- Brain dysfunction: Correlates with consciousness impairment
- Prognosis: Higher mortality in SAE patients with elevated HMGB1
| Method |
Sensitivity |
Sample Types |
| ELISA |
~0.1 ng/mL |
CSF, serum, plasma |
| Western blot |
Medium |
All |
| Mass spectrometry |
High |
Research |
| Multiplex panels |
High |
Luminex, Simoa |
| Sample |
Normal |
Elevated |
| Serum (ng/mL) |
1-5 |
>5 |
| CSF (ng/mL) |
0.5-2 |
>2 |
- TLR4 activation: Binds to Toll-like receptor 4, activating microglia
- RAGE engagement: Interacts with RAGE receptor
- Cytokine cascade: Induces IL-1β, TNF-α, IL-6 production
- NF-κB activation: Promotes inflammatory gene expression
- Chemotaxis: Attracts immune cells to site of injury
- Excitotoxicity enhancement
- Mitochondrial dysfunction
- Oxidative stress
- Blood-brain barrier disruption
- Inhibition of neurogenesis
- Amyloid-beta: HMGB1-Aβ complexes are more toxic
- α-Synuclein: May promote aggregation
- Tau: May facilitate spread
- SOD1: In ALS models
- Neutralizing antibodies: Anti-HMGB1 antibodies in clinical trials
- Small molecule inhibitors: Glycyrrhizin (natural compound)
- Box A domain: Recombinant HMGB1 Box A (antagonist)
- TLR4 antagonists: Block downstream signaling
- Anti-HMGB1 in sepsis (completed)
- Anti-HMGB1 in traumatic brain injury (ongoing)
- Glycyrrhizin in various inflammatory conditions
- Biomarker validation: Large longitudinal studies
- Multi-analyte panels: Combining with NfL, tau
- Therapeutic targeting: Clinical trials of HMGB1 inhibition
- Mechanism studies: Understanding dual roles (neuroprotection vs. neurotoxicity)
The study of High Mobility Group Box 1 (Hmgb1) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- HMGB1 in Alzheimer's - PubMed
- HMGB1 in Parkinson's - PubMed
- HMGB1 as damage signal - PubMed
- HMGB1 in stroke - PubMed
- HMGB1 in TBI - PubMed
- HMGB1 in ALS - PubMed
- HMGB1 and neuroinflammation - PubMed
- HMGB1 gene - NCBI Gene
- HMGB1 protein - UniProt